FDA to review Zynquista™ (sotagliflozin) as potential treatment for type 1 diabetes

FDA to review Zynquista™ (sotagliflozin) as potential treatment for type 1 diabetes

BRIDGEWATER, N.J. and THE WOODLANDS, Texas, May 22, 2018 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) has accepted Sanofi’s regulatory filing for Zynquista (sotagliflozin). The investigational oral treatment would be used in addition to insulin therapy to improve blood sugar control in adults

Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis

​​​May 16, 2018 U.S. regulatory submission for patients ages 12-17 planned for third quarter 2018   Paris and Tarrytown, NY – May 16, 2018 – A pivotal Phase 3 trial evaluating Dupixent® (dupilumab) to treat moderate-to-severe atopic dermatitis in adolescents (ages 12-17)

Sanofi and Ablynx Announce the Successful Results of the Initial Tender Offer Period for Ablynx and Commencement of Squeeze-Out Tender Period

Paris, France and Ghent, Belgium – May 14, 2018 – Sanofi (Euronext: SAN; NYSE: SNY) and Ablynx (Euronext Brussels and Nasdaq: ABLX) today announced the results of the initial tender offer period of Sanofi’s previously announced tender offers to acquire all

Annual General Shareholders’ Meeting of May 2, 2018

Shareholders’ approval of the financial statements for 2017 Dividend of €3.03 per share payable as of May 15, 2018 Board Composition: renewals and appointment Paris (France) – May 2, 2018 – The Combined General Shareholders’ Meeting of Sanofi was held today

FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma

Paris and Tarrytown, NY – April 30, 2018 – The U.S. Food and Drug Administration (FDA) has accepted priority review the Biologics License Application (BLA) for cemiplimab for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or patients

Sanofi Head of Global R&D Elias Zerhouni to retire; Company names John Reed to take over on July 1

Paris – 24th April 2018   — Elias Zerhouni, M.D., Head of Global Research and Development will retire from Sanofi on June 30th, 2018, after more than 9 years of distinguished service with the company. He will be succeeded in the post by

Advent International enters into exclusive negotiations to acquire Zentiva, Sanofi’s European generics business

Advent to invest in Zentiva to create a new, independent European generics leader. Divestiture of European generics, a non-core business, is part of Sanofi’s strategy to simplify and reshape the Company. Transaction anticipated before end of the year, following consultation